Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating

Investing.com

Published Jul 01, 2025 07:40AM ET

Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating

Investing.com - Cantor Fitzgerald initiated coverage on Trevi Therapeutics (NASDAQ:TRVI), currently trading at $5.47 with a market cap of $652 million, with an Overweight rating and a $25 price target, representing approximately 300% upside from current levels. The stock has shown strong momentum, delivering an impressive 89% return over the past year, according to InvestingPro data.

The research firm described its recommendation as a high-conviction call for Trevi's pre-commercial program developing Haduvio, a mixed opioid agonist/antagonist for chronic cough conditions. Cantor Fitzgerald noted that Haduvio has demonstrated consistent and strong reductions in cough of more than 50% across multiple Phase 2 studies in both interstitial pulmonary fibrosis (IPF) and refractory chronic cough (RCC). InvestingPro data shows the company maintains a strong financial position with a current ratio of 15.38 and minimal debt relative to its cash position.

Trevi Therapeutics plans to begin a Phase 3 trial for IPF chronic cough in the first half of 2026, with projected enrollment completion within a year and topline data expected by mid-2027. The company anticipates filing for regulatory approval in 2028, though Cantor Fitzgerald suggests enrollment could proceed faster than expected given the size of the patient population and unmet need.

Haduvio is the first and only drug to show positive data for both chronic cough in IPF and RCC, according to the research firm. The drug is currently completing Phase 2 development for these indications.

Additional clinical studies are expected to generate news flow while the Phase 3 trial progresses, including a Phase 2 study for non-IPF interstitial lung disease that should report results by the end of 2026, and an advancing Phase 2b study in refractory chronic cough. With analyst targets ranging from $13 to $29, and the next earnings report due on August 7, investors can access comprehensive analysis and 10+ additional key insights through InvestingPro 's detailed research report.

In other recent news, Trevi Therapeutics announced positive results from its Phase 2b CORAL trial, which evaluated Haduvio for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF-CC). The trial demonstrated statistically significant reductions in 24-hour cough frequency, with the 108 mg BID dose achieving a placebo-adjusted change of -43.3%. Following these results, H.C. Wainwright, Stifel, and Raymond James maintained their Buy ratings on Trevi's stock, with Raymond James setting a price target of $29. Oppenheimer also raised its price target to $23, citing the strong trial outcomes and the absence of approved treatment options for IPF-CC. Trevi plans to initiate its Phase 3 program in the first half of 2026 after an End-of-Phase 2 meeting with the FDA. Additionally, Trevi Therapeutics launched a $100 million public offering of common stock, with an option for underwriters to purchase an additional $15 million in shares. The offering is subject to market conditions, and a preliminary prospectus supplement will be filed with the SEC. These developments highlight Trevi's ongoing efforts to advance Haduvio as a leading treatment for chronic cough conditions.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes